Tokyo, Oct. 15 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063234) titled 'Real-World Clinical Practice of Generalized Anxiety Disorder (GAD) Among Physicians' on Oct. 15.
Study Type:
Observational
Primary Sponsor:
Institute - Viatris Pharmaceuticals Japan G.K.
Condition:
Condition - Generalized anxiety disorder
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To investigate the current status of the diagnosis and treatment of generalized anxiety disorder (GAD) among psychiatrists and psychosomatic medicine physicians in Japan, and to clarify changes in physicians' awareness and clinical practice since the previous survey conducted in December 2022. This study also aims to identify unmet needs in GAD treatment that remain after the approval of an additional indication for GAD.
Basic objectives2 - Others
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - 1.Provide informed consent to participate in the study on the web.
2.Main clinical department is psychiatry or psychosomatic medicine.
3.Physicians who have treated 10 or more outpatients or 10 or more inpatients in the past month.
Key exclusion criteria - None
Target Size - 500
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 09 Month 16 Day
Date of IRB - 2026 Year 09 Month 16 Day
Anticipated trial start date - 2026 Year 10 Month 20 Day
Last follow-up date - 2026 Year 10 Month 28 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072360
Disclaimer: Curated by HT Syndication.
